Lumera NGS Profile for Solid Tumor

Molecular

81479

This next-generation sequencing (NGS) test is designed to profile the molecular abnormalities in various solid tumors including cancers of the lung, pancreas, brain, colon, breast, ovary, endometrium, thyroid, head and neck, and soft tissue (sarcoma and GIST). NGS analysis covers both DNA sequencing (523 genes) and RNA sequencing (55 genes), as well as copy number variation (CNV), tumor mutational burden (TMB), microsatellite instability (MSI), and RNA fusions and missplicing. The results provide physicians with clinically actionable information to aide in determining prognosis, designing therapeutic approach, and predicting response to therapy.

• Formalin-Fixed Paraffin-Embedded Tissue: FFPE blocks are preferred and can be sent for sectioning in our lab. Alternatively, the lab can accept 1 H&E slide and 10 unstained slides cut to 4-5 microns of tissue fixed with 10% NBF fixative on non-charged slides. Please circle tumor for microdissection.

Ship specimen the same day whenever possible, with refrigerated (not frozen) cold pack.

Label all tubes with at least two unique patient identifiers. Slides require one patient identifier. Identifiers include name, DOB, specimen ID# or medical record#.

10-14 Days

Global